Immunity against Actinobacillus pleuropneumoniae's RTX toxins APX
AssigneesCommonwealth Scientific and Industrial Research Organisation, Pig Research and Development Corporation
InventorsChristopher Thomas Prideaux, Adrian Leslie Mark Hodgson
Life of this patent
Estimating the term…
Abstract
Disclosed herein is a modified microorganism which produces an RTX toxin, wherein said RTX toxin is partially or fully inactivated. Also disclosed is a modified microorganism wherein an RTX toxin gene including an RTX structural gene and/or a post-translational activator of the organism is partially or full inactivated. As disclosed, the precursor of an RTX toxin has reduced toxic activity.
Claims15
A genetically modified strain of Actinbacillus pleuropneumoniac (APP) comprising an operon including an RTX A gene and an inactivated RTX C gene and wherein an RTX structural polypeptide is encoded by the RTX A gene and wherein activation of said RTX structural polypeptide is prevented by the inactivated RTX C gene prior to secretion and wherein said RTX structural polypeptide is secreted in a non-toxic form and induces, in a host, protective immunity to the RTX toxin and infection by APP.
A method of producing a recombinantly modified APP which produces an RTX structural polypeptide wherein said RTX structural polypeptide is inactivated, said method comprising providing an APP producing an active RTX structural polypeptide, and an inactivated RTX C gene.
Dependencies are inferred from the claim text.